Up­dat­ed: Ex-Seagen chief Clay Sie­gall emerges as CEO of pri­vate biotech

Clay Sie­gall will be back in the CEO seat, tak­ing the helm of a pri­vate start­up work­ing on tar­get­ed can­cer ther­a­pies.

It’s been al­most a year since Sie­gall re­signed from Seagen, the biotech he co-found­ed and led for more than 20 years, in the wake of do­mes­tic vi­o­lence al­le­ga­tions by his then-wife. His even­tu­al suc­ces­sor, David Ep­stein, sold the com­pa­ny to Pfiz­er in a $43 bil­lion deal un­veiled last week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER